Summary
Danaher Corporation reported solid performance for the fiscal year ending December 31, 2022, demonstrating resilience amidst economic uncertainties and supply chain challenges. The company achieved total sales growth of 7.0%, driven by a 9.5% increase in core sales, indicating strong underlying business performance. Net earnings from continuing operations rose to $7.2 billion, up from $6.3 billion in the prior year. The company's diverse segment structure, encompassing Biotechnology, Life Sciences, Diagnostics, and Environmental & Applied Solutions, contributed to this growth, with strong performance noted across several key areas, including molecular diagnostics and bioprocessing. Danaher also reaffirmed its commitment to strategic capital allocation and operational excellence through the Danaher Business System (DBS). Looking ahead, Danaher announced its intention to separate its Environmental & Applied Solutions (EAS) segment into a standalone publicly traded company in the fourth quarter of 2023, a move expected to unlock further value. Despite facing headwinds such as supply chain disruptions and inflation, which were largely mitigated through DBS, the company's strategic focus on innovation, customer service, and attracting top talent positions it well for continued growth and value creation. Investors should note the ongoing management of global operations and adaptation to market dynamics, including the impact of foreign currency fluctuations.
Financial Highlights
53 data points| Revenue | $26.64B |
| Cost of Revenue | $10.46B |
| Gross Profit | $16.19B |
| R&D Expenses | $1.53B |
| SG&A Expenses | $7.12B |
| Operating Income | $7.54B |
| Interest Expense | $204.00M |
| Net Income | $7.10B |
| EPS (Basic) | $9.80 |
| EPS (Diluted) | $9.66 |
| Shares Outstanding (Basic) | 725.10M |
| Shares Outstanding (Diluted) | 737.10M |
Key Highlights
- 1Total sales increased by 7.0% to $31.5 billion, with core sales growing by 9.5%, demonstrating strong organic growth.
- 2Net earnings from continuing operations increased to $7.2 billion, up from $6.3 billion in the prior year.
- 3The company announced its intention to spin off its Environmental & Applied Solutions (EAS) segment in Q4 2023, aiming to create a focused, independent entity.
- 4Danaher managed to largely mitigate the impact of supply chain disruptions, cost inflation, and labor cost increases through its Danaher Business System (DBS), although these pressures continue to varying degrees.
- 5The Biotechnology segment saw sales grow by 2.0%, driven by core sales growth in bioprocessing and discovery/medical businesses, despite a decline in COVID-19 related product demand.
- 6The Diagnostics segment reported a 10.0% increase in total sales, primarily driven by strong demand for molecular diagnostics, including COVID-19 tests, and growth in clinical and pathology diagnostics.
- 7The company ended the year with a strong liquidity position, with $6.0 billion in cash and cash equivalents.
- 8Danaher reiterated its strategic priorities of strengthening competitive advantage via DBS, enhancing its portfolio through strategic capital allocation, and attracting exceptional talent.